FDA requires new warning label for GLP-1 drugs over rare vision-loss risk
The FDA announced that manufacturers of GLP-1 medications must add a label warning about a possible increase in the risk of non-arteritic anterior ischemic optic neuropathy, a rare condition often called “eye stroke.”
The U.S. Food and Drug Administration issued updated labeling rules for glucagon-like peptide-1 (GLP-1) medications, requiring manufacturers to warn that the drugs may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare form of vision loss sometimes described as an “eye stroke.”
Northwestern University ophthalmology professor Manjot Gill said the condition is very uncommon, affecting roughly 2 to 10 people per 100,000 annually among those over age 50, and that existing studies have produced mixed results on whether GLP-1 drugs raise the risk. She emphasized that patients should discuss potential risks with their physicians and report any sudden vision changes promptly.
Gill added that, for most individuals, the therapeutic benefits of GLP-1 drugs—including improvements in blood sugar, blood pressure and cholesterol—far outweigh the low probability of this eye complication. The FDA’s action reflects a precautionary approach while further research evaluates the association.